Lionco(SH:603669) Zheng Quan Zhi Xing·2025-06-20 10:13Group 1 - The company, Lingkang Pharmaceutical Group Co., Ltd., has publicly issued A-share convertible bonds with a total amount of RMB 517.78 million, consisting of 5.25 million bonds at a face value of RMB 100 each [1][4][9] - The bonds are convertible into the company's A-shares, with an initial conversion price set at RMB 8.81 per share, and the conversion period is from June 7, 2021, to November 30, 2026 [2][3][4] - The company has established a special account for the raised funds, which will be used for specific investment projects, including the construction of a production base [9][10][15] Group 2 - In 2024, the company reported a revenue of RMB 379.78 million, a 92.95% increase from RMB 196.83 million in 2023, but incurred a net loss of RMB 130.76 million, an improvement from a loss of RMB 151.50 million in the previous year [12][13] - The total assets decreased by 22.73% to RMB 1.26 billion from RMB 1.62 billion in 2023, and the net assets also fell by 17.32% to RMB 769.76 million [12][13] - The company has terminated the "Hainan Lingkang Pharmaceutical Production Base Construction Project (Phase I)" due to significant changes in project feasibility and will retain the remaining raised funds in the special account [14][15] Group 3 - The company has a credit rating of A- for its bonds as of June 2024, with a stable outlook, reflecting a downgrade from AA- in previous years [12][13] - The company has implemented measures to ensure compliance with regulations regarding the use of raised funds, and there have been no violations reported [10][14] - The company has established a management system for the raised funds, ensuring they are used appropriately for the intended projects [10][14]